Verinata Health will use Illumina's HiSeq 2000 sequencer to commercialize its non-invasive prenatal test for the detection of multiple aneuploidies, the company said last week.
Under a three-year supply agreement, Verinata will purchase Illumina's sequencing instruments and consumables, and the two partners will collaborate in obtaining regulatory approval for the testing service.
Specifically, the supply agreement will "provide uninterrupted access" to Illumina's HiSeq 2000 and consumables, including "certain updates and improvements applied to current technology," said Verinata CEO Caren Mason in a statement.
Verinata is developing a non-invasive prenatal diagnostic test for trisomy 21 and other fetal aneuploidies, which it plans to launch later this year or in early 2012. This summer, the company raised $46.5 million in a Series C venture capital financing round (CSN 8/9/2011).
Sequenom and LifeCodexx are also developing sequencing-based prenatal tests for trisomy 21. Sequenom, which plans to launch its MaterniT21 test either later this year or early next year, signed a similar supply agreement with Illumina this summer (CSN 6/12/2011).